81 results
Page 2 of 5
8-K
tbt 4odngvj7
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
8-K
EX-99.1
cjh7re3c5 mnw7e2
28 Jun 22
Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer
4:02pm
8-K
EX-99.1
8mft j70ahr531l8zrn
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.3
veit eihi
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
o9221nl1678a0ko
12 May 22
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
4:52pm
8-K
EX-99.1
41opggpoc do
24 Mar 22
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
07c8el8
17 Feb 22
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring
8:37am
8-K
EX-99.1
aae eiegh9wbq
19 Jan 22
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739
7:42am
8-K
EX-99.1
a77uzf4iyfvtb
15 Nov 21
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
7:42am
8-K
EX-99.2
irwre98ks
10 Nov 21
Regulation FD Disclosure
7:12am
8-K
EX-99.1
hyd05tys yv3ekil
16 Aug 21
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
7:21am
8-K
EX-99.1
sn2rwj6qmj7 cofd6i2
12 Aug 21
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
5bra90pq51j40x1
13 May 21
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
4:00pm